Differentiated Product
Team Catanzaro is a SMID-Cap Biotech team with a coverage focus on clinically de-risked programs in oncology and immunology. The team has launched on 14 names since October 2025 with each offering proprietary insights into future data readouts. The team anchors itself in its deep scientific knowledge and thorough data analysis offering unique data points around probabilities of success, exposure-response modeling and competitive positioning. Since launching coverage the team has provided differentiated analyses ahead of high impact catalysts including Revolution Medicines’ RASolute 302 study of daraxonrasib in pancreatic cancer, Kymera’s initial data in atopic dermatitis for KT-621, Apogee’s Phase II induction and maintenance data for zumilokibart in atopic dermatitis, Spyre’s Phase II induction data for SPY001, SPY002 and SPY003 in ulcerative colitis and Avalo’s Phase II readout of abdakibart in hidradenitis suppurativa, among several others.
Key Reports
- Revolution Medicines (RVMD) – Thinking a Little Bit About RASolute 302 Timing in 2026
- Revolution Medicines (RVMD) – Preview: Opportunity for Some More 1L PDAC Validation
- Spyre Therapeutics (SYRE) – Preview: Painting a Vibrant UC SKYLINE
- Apogee Therapeutics (APGE) – Preview: Getting Acquainted With Maintenance
- Apogee Therapeutics (APGE) – Preview: High Dose Induction & Another Opportunity for Zumi to Solidify its Profile in AD
- PDAC KOL Call Highlights; Poised for a Remarkable Shift in the Treatment Paradigm
- Atopic Dermatitis KOL Call Highlights; New Therapies From CRVS, KYMR & APGE Excite
- Positive Bexdeg/CLL Update, Favorable KOL Feeback, STAT6 Validation; PT to $30
Notable Events
- Pancreatic Cancer KOL Call (March 2026)
- Avalo Therapeutics Management Dinner (March 2026)
- Atopic Dermatitis KOL Call (January 2026)
- CLL KOL Lunch at ASH (December 2025)
- Elevidys Label Expansion, and ALKS 2680 and the Orexin 2 Receptor Agonists class
Analyst Bio
Joe has more than ten years of experience covering the sector, including the last seven as a senior biotechnology analyst focused on oncology at Piper Sandler. There, he co-developed the firm’s monthly BioInsights deep dive series popular with clients, as well as private companies and VCs. He also co-developed BioInsights Key Opinion Leader Days consisting of five KOL panels that drew attendance from clients across the firm’s top accounts. Prior to that, at Cowen, he led the production of its biannual Investor’s Guide to Immuno-Oncology. While earning a Ph.D. in genetics, with a focus on cancer cell biology and translational oncology, he was the lead author on two academic papers and co-author on two others. Joe received his Ph.D. from the Stony Brook University School of Medicine and a B.S., in Biological Sciences from Binghamton University.